NCT04640779View on ClinicalTrials.gov

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2027

Conditions
Recurrent Histiocytic and Dendritic Cell NeoplasmRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell MyelomaRefractory Histiocytic and Dendritic Cell NeoplasmRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Choline Salicylate

Given PO

DRUG

Selinexor

Given PO

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER